{"id":151591,"date":"2026-10-28T12:08:41","date_gmt":"2026-10-28T12:08:41","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/151591\/"},"modified":"2026-10-28T12:08:41","modified_gmt":"2026-10-28T12:08:41","slug":"roche-launches-ventana-bap1-mesothelioma-test","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/151591\/","title":{"rendered":"Roche Launches VENTANA BAP1 Mesothelioma Test"},"content":{"rendered":"<p><a href=\"https:\/\/vohnetwork.com\/tag\/roche\" class=\"voh-inline-tag\" data-tag-id=\"272\" data-tag-slug=\"roche\" data-tag-name=\"Roche\" title=\"View all news tagged Roche\" rel=\"nofollow noopener\" target=\"_blank\">Roche<\/a> has announced the global launch of the VENTANA BAP1 (SP527) test, an automated immunohistochemistry (IHC) assay designed to help clinicians and pathologists distinguish malignant mesothelioma from other cancers, including non-small cell lung cancer (NSCLC), and benign tissue growths.<\/p>\n<p>Mesothelioma is a rare and aggressive cancer affecting the lining of internal organs. More than 80% of cases occur in the pleural cavity, which surrounds the lungs. Many patients are diagnosed at an advanced stage, with a median overall survival of just 12 to 18 months.<\/p>\n<p>The VENTANA BAP1 (SP527) test detects the loss of nuclear BAP1 expression, a marker that can help identify malignancy in mesothelial tissue. The assay is registered as a Class I in vitro diagnostic with the U.S. Food and Drug Administration and has received Class C approval under the European In Vitro Diagnostic Regulation (IVDR). It is available globally.<\/p>\n<p>\u201cTimely differential diagnosis of mesothelioma is critical to help deliver the best outcome for patients,\u201d said Matt Sause, CEO of Roche Diagnostics. \u201cAdding BAP1 to our portfolio underscores our commitment to developing innovative solutions that enable healthcare systems around the world to address diseases with high unmet need, such as mesothelioma.\u201d<\/p>\n<p>A key challenge in lung cancer and mesothelioma diagnosis is preserving limited tissue samples for essential testing. Roche\u2019s BAP1 assay, alongside its VENTANA MTAP (SP530) and VENTANA Claudin-4 (EP417) tests, is designed to help pathologists distinguish malignant disease from other conditions while minimising tissue loss. This can help preserve samples for molecular sequencing and precision medicine testing.<\/p>\n<p>Roche\u2019s lung cancer diagnostic portfolio includes tissue diagnostics, immunohistochemistry assays, molecular testing such as PCR and next-generation sequencing, core laboratory immunoassays and navify\u00ae digital software. The company says these solutions aim to support diagnostic accuracy and patient management across the care pathway.<\/p>\n<p>Lung cancer remains the leading cause of cancer death worldwide, with more than 2.5 million people diagnosed globally each year. Up to 85% of these cases are non-small cell lung cancer, highlighting the importance of reliable diagnostic tools.<\/p>\n<p>Explore <a href=\"https:\/\/vohnetwork.com\/news\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Health News<\/a> in India alongside the <a href=\"https:\/\/vohnetwork.com\/news\/diagnostics\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">latest diagnostics news<\/a> and laboratory developments and upcoming <a href=\"https:\/\/vohnetwork.com\/events\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">healthcare conferences.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche has announced the global launch of the VENTANA BAP1 (SP527) test, an automated immunohistochemistry (IHC) assay designed&hellip;\n","protected":false},"author":2,"featured_media":151592,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[42433,71659,71661,71660,71658,71663,71662,134,2057,71656,71657],"class_list":["post-151591","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-cancer-diagnostics","tag-immunohistochemistry-assay","tag-lung-cancer-diagnostics","tag-malignant-mesothelioma","tag-mesothelioma-diagnosis","tag-oncology-diagnostics","tag-precision-medicine-testing","tag-roche","tag-roche-diagnostics","tag-roche-ventana-bap1","tag-ventana-bap1-sp527"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117518461027629930","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/151591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=151591"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/151591\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/151592"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=151591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=151591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=151591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}